Oncology is a big investment target – here’s what investors care about
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Pharma is making inroads into digital health, albeit slowly
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
US slower than Europe, emerging markets in liquid biopsy adoption
Blood-based cancer tests have market, but more evidence may be needed to verify validity and utility.